Creating synthetic circuits to control cell differentiation for blood cell production
Official title: Synthetic Genetic Controller Circuits for Transcription Factor-Directed Differentiation
Funded at Massachusetts Institute of Technology · NIH-11117441 · Data updated 2026-11-12
This study is working on a new way to help turn special stem cells into specific types of blood cells more effectively, which could lead to better treatments for patients needing blood-related therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | August 6, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $600,000 |
| NIH project number | 1R56EB036090-01 |
| Project ID | NIH-11117441 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research would include individuals with blood-related conditions who may require stem cell therapies.
✕Less likely to help
Patients with conditions unrelated to blood cell production or those who are not eligible for stem cell therapies may not receive benefits from this research.
What this research studies
This research aims to develop synthetic genetic circuits that can autonomously regulate the expression of transcription factors critical for differentiating human induced pluripotent stem cells (hiPSCs) into specific blood cell types. By improving the efficiency and consistency of this differentiation process, the research seeks to address current challenges in producing hematopoietic stem and progenitor cells, which are essential for various blood-related therapies. The approach involves optimizing the timing and levels of transcription factor expression to enhance the quality of the resulting cells. Patients may benefit from advancements in cell therapy and regenerative medicine as a result of this work.
Why it matters
Potential benefit: If successful, this research could lead to more efficient and reliable production of blood cells for therapies, improving treatment options for patients with blood disorders.
How similar studies have gone: Previous research has shown promise in using synthetic genetic circuits for cell differentiation, indicating potential for success in this novel approach.
Where this research is happening
-
Massachusetts Institute of Technology
Cambridge, United States Active
Researchers
- Principal investigator: Del Vecchio, Domitilla — Massachusetts Institute of Technology
- Study coordinator: Del Vecchio, Domitilla
Related research
Other NIH-funded projects on the same topics.
-
PhysioNet: A trusted, open data repository for clinical and physiological data
A publicly accessible platform provides curated clinical and physiological data and tools to help researchers develop and test AI models for better healthcare.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Single-cell, label-free mapping of senescence in tissues with Raman imaging and spatial genomics
A project to map how senescent cells differ across tissues using a noninvasive Raman imaging method combined with spatial genomics.
-
Structures and dynamics of virus ion channels
This project studies the tiny channels in certain influenza and coronavirus viruses to understand how they let ions pass through and contribute to disease.
-
Prospect: Stem Cell Models for Early-Onset Colorectal Cancer Prevention
Researchers at MIT are using stem cell models to understand why colorectal cancer is rising in people under 50 and how to prevent it.
-
MATCHMAKERS: AI tools to predict TCR binding and design
Researchers are building AI tools to predict how T cell receptors recognize tumor antigens, with aims to help improve targeted immunotherapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.